You are here:

Archived: co-careldopa intestinal gel, 20mg/5mg levodopa/cabidopa per ml for continuous intestinal infusion (Duodopa)

Advice

Following a full submission

co-careldopa intestinal gel (Duodopa) is not recommended for use within NHS Scotland for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.

In the pivotal study an increase in “on” time was achieved compared with individually optimised conventional combinations of Parkinson’s disease medication. However, the economic case has not been demonstrated.

Drug Details

Drug Name: co-careldopa intestinal gel, 20mg/5mg levodopa/cabidopa per ml for continuous intestinal infusion (Duodopa)
SMC Drug ID: 316/06
Manufacturer: Solvay Healthcare Ltd
Indication: Parkinson’s disease
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 October 2006

Current Advice

Resubmission 13 June 2016

Archived Advice

Resubmission 7 December 2015

Back